Skip to content

Role of tranexamic acid in controlling bleeding in spine surgeries.

Role of tranexamic acid in reducing peri-operative blood loss in open spinal surgeries.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/06/034209
Enrollment
100
Registered
2021-06-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M96-M96- Intraoperative and postprocedural complications and disorders of musculoskeletal system, not elsewhere classified

Interventions

Intervention1: Tranexamic acid: 1 gram of injection tranexamic acid is given intravenously thirty minutes before skin incision Intervention2: No treatment: No treatment

Sponsors

Kasturba medical college
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All open spine surgeries. 2. Patients with age 18 years and greater. 3. Patients with low risk of anaesthesia related complications( i.e. ASA I and ASA II patients ). will be enrolled for the study.

Exclusion criteria

Exclusion criteria: 1.Minimally invasive spine surgeries and unilateral single level fenestration discectomies. 2.Patients with age less than 18 years. 3.Patients with blood dyscrasias ,coagulation profile abnormality and renal disorders. 4.Patients with high risk of anaesthesia related complications ASA III and ASA IV patients. 5.Duration of surgery more than 6 hours. 6.Patients on medication which can interfere with tranexamic acid such as aspirin ,clopidogrel , dabigatran , heparin , enoxaparin , fondaparinux. will be excluded from the study.

Design outcomes

Primary

MeasureTime frame
1.Intraoperative blood loss in the group of patients receiving tranexamic acid and in the group of patients not receiving tranexamic acid. 2.Assessment of drop in 24 hour hemoglobin in the group of patients receiving tranexamic acid and in the group of patients not receiving tranexamic acid . 3.Assessment of postoperative drain output in the group of patients receiving tranexamic acid and in the group of patients not receiving tranexamic acid . Timepoint: one the day of surgery and upto 3 days postoperatively

Secondary

MeasureTime frame
NATimepoint: NA

Countries

India

Contacts

Public ContactDr Shyamasunder Bhat N

Kasturba Medical College, MAHE

shyambhat.n@manipal.edu9480486075

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026